First Case Report: CGRP Antibody Erenumab Improved Both Migraine and Writer's Cramp in a Single Patient
A patient with comorbid migraine and writer's cramp (focal task-specific dystonia) experienced improvement in both conditions after 3 months of erenumab treatment — the first reported case suggesting CGRP may play a role in dystonia pathophysiology.
Quick Facts
What This Study Found
Erenumab treatment for 3 months improved symptoms of both focal task-specific dystonia (writer's cramp) and migraine in a single patient. This is the first case report of CGRP mAb improving dystonia, suggesting a potential role for CGRP in dystonia pathophysiology.
Key Numbers
First reported case of anti-CGRP mAb improving dystonia. Patient had both migraine and writer's cramp.
How They Did This
Single case report. Patient with comorbid migraine and writer's cramp treated with erenumab (CGRP receptor antibody) due to increasing monthly migraine days. Both conditions assessed clinically before and after 3 months of treatment.
Why This Research Matters
Writer's cramp and other focal dystonias are difficult to treat — botulinum toxin injections are the main option but have limitations. If CGRP is involved in dystonia pathophysiology, CGRP antibodies could represent an entirely new treatment approach for these debilitating movement disorders.
The Bigger Picture
CGRP antibodies continue to reveal effects beyond migraine. This case report, while preliminary, suggests CGRP may be involved in the neural circuits that produce dystonia — expanding our understanding of CGRP biology and potentially opening new therapeutic applications for an established drug class.
What This Study Doesn't Tell Us
Single case report — the lowest level of evidence. Could be coincidental improvement, placebo effect, or natural disease fluctuation. No objective dystonia measures described. Cannot establish causation from a single observation.
Questions This Raises
- ?Is the dystonia improvement reproducible in other patients with comorbid migraine and focal dystonia?
- ?Does CGRP play a role in dystonia neural circuits, or was the improvement secondary to migraine reduction?
- ?Should a prospective trial of CGRP antibodies in focal dystonia patients be pursued?
Trust & Context
- Key Stat:
- First case of CGRP mAb improving dystonia A patient with writer's cramp saw improvement after 3 months of erenumab, originally prescribed for migraine — no prior reports have linked CGRP antibodies to dystonia improvement
- Evidence Grade:
- Rated preliminary: single case report with no control, no objective measures, and potential for coincidental improvement. Important as hypothesis-generating but not evidence for treatment efficacy.
- Study Age:
- Published in 2024. Represents an emerging observation about CGRP's role beyond pain and migraine.
- Original Title:
- Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
- Published In:
- Neuropsychopharmacology reports, 44(2), 482-484 (2024)
- Authors:
- Suzuki, Keisuke(4), Suzuki, Shiho(3), Fujita, Hiroaki(2), Sakuramoto, Hirotaka, Shioda, Mukuto, Hirata, Koichi
- Database ID:
- RPEP-09350
Evidence Hierarchy
Frequently Asked Questions
Can CGRP antibodies help with movement disorders like writer's cramp?
This is only a single case report, so we can't say for certain. One patient with both migraine and writer's cramp saw improvement in both after starting erenumab. It's intriguing and suggests CGRP might be involved in dystonia, but much more research is needed before CGRP drugs could be recommended for movement disorders.
What is writer's cramp and how is it usually treated?
Writer's cramp is a type of focal dystonia where hand muscles involuntarily contract during writing, making it difficult or impossible. It's currently treated mainly with botulinum toxin injections, which temporarily weaken the affected muscles. Effective long-term treatments are limited, which is why this case report of improvement with erenumab is noteworthy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09350APA
Suzuki, Keisuke; Suzuki, Shiho; Fujita, Hiroaki; Sakuramoto, Hirotaka; Shioda, Mukuto; Hirata, Koichi. (2024). Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?. Neuropsychopharmacology reports, 44(2), 482-484. https://doi.org/10.1002/npr2.12444
MLA
Suzuki, Keisuke, et al. "Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?." Neuropsychopharmacology reports, 2024. https://doi.org/10.1002/npr2.12444
RethinkPeptides
RethinkPeptides Research Database. "Can calcitonin gene-related peptide monoclonal antibodies am..." RPEP-09350. Retrieved from https://rethinkpeptides.com/research/suzuki-2024-can-calcitonin-generelated-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.